Veeva releases key details from European Life Sciences Survey
pharmafile | December 6, 2016 | News story | | veeva
Veeva, which held its European Life Sciences Summit last week, has announced some of the key findings from its European Life Sciences Survey. The major statistics revealed were that companies wait an average of 10 days for changes to customer data to be processed, while 87% of survey respondents have issues with data quality. The importance of data issues was tied to the desire of the respondents to improve sales and marketing efficiency (77%), and to improve analysis and decision-making (76%).
Speaking to Pharmafocus, Guillaume Roussel, director of strategy at Veeva OpenData, Europe, warned, “If the essential foundations of consistent, high-quality customer data are not available to companies, then business projects will probably fail at some point.”
He continued, “It’s vital to have these foundations in place in order to feed and nurture business intelligence, and ultimately enable companies to develop the correct strategy and tactics for their market.”
Veeva hopes to step in to aid those companies that struggle with the issues discovered by the survey with its customer reference data, which is specific for the life sciences industry and available for use without customisation. The study found that 78% of respondents are already looking to, or are planning to in the next two years, improve upon the quality of their data. This is an area that Veeva believes it will be able to capitalise upon, especially as half of respondents are currently dissatisfied with the quality of their data.
Veeva’s European Life Sciences Survey’s aim is to assess the state of data quality within the life sciences industry by contacting companies in Europe. The bulk of the more than 80 respondents were from France, Germany, the UK, Italy and Spain. The full findings from the European Life Sciences Survey will be released in January 2017.
Related Content
2020 Veeva Unified Clinical Operations Survey
Every year, Veeva asks clinical professionals to take part in the Veeva Unified Clinical Operations …
Three focus areas to accelerate breakthrough drugs to market
The number of clinical trials taking place each year continues to rise. In fact, in …
Using advanced digital capabilities to unlock hard-to-see HCPs access
Pharmaceutical companies face a ‘digital imperative’ to engage with healthcare professionals through their channel preferences …
